JP2015536301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536301A5 JP2015536301A5 JP2015535891A JP2015535891A JP2015536301A5 JP 2015536301 A5 JP2015536301 A5 JP 2015536301A5 JP 2015535891 A JP2015535891 A JP 2015535891A JP 2015535891 A JP2015535891 A JP 2015535891A JP 2015536301 A5 JP2015536301 A5 JP 2015536301A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- composition according
- urine
- measuring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 210000002700 urine Anatomy 0.000 claims 19
- 239000002777 nucleoside Substances 0.000 claims 17
- 108091034117 Oligonucleotide Proteins 0.000 claims 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 12
- 210000004369 blood Anatomy 0.000 claims 11
- 239000008280 blood Substances 0.000 claims 11
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 208000003215 hereditary nephritis Diseases 0.000 claims 9
- 208000024985 Alport syndrome Diseases 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 229940109239 creatinine Drugs 0.000 claims 6
- 201000001474 proteinuria Diseases 0.000 claims 6
- 206010001580 Albuminuria Diseases 0.000 claims 4
- 102000008186 Collagen Human genes 0.000 claims 4
- 108010035532 Collagen Proteins 0.000 claims 4
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims 4
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 claims 4
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 claims 4
- 229920001436 collagen Polymers 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000003907 kidney function Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 210000000557 podocyte Anatomy 0.000 claims 4
- 108010055851 Acetylglucosaminidase Proteins 0.000 claims 3
- 102000004266 Collagen Type IV Human genes 0.000 claims 3
- 108010042086 Collagen Type IV Proteins 0.000 claims 3
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 3
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims 3
- 102000003810 Interleukin-18 Human genes 0.000 claims 3
- 108090000171 Interleukin-18 Proteins 0.000 claims 3
- -1 LNA nucleoside Chemical class 0.000 claims 3
- 102100030122 Protein O-GlcNAcase Human genes 0.000 claims 3
- 230000001934 delay Effects 0.000 claims 3
- 208000006750 hematuria Diseases 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 108091062762 miR-21 stem-loop Proteins 0.000 claims 3
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims 3
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims 3
- 125000003835 nucleoside group Chemical group 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000005862 Angiotensin II Human genes 0.000 claims 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 2
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 2
- 101800000733 Angiotensin-2 Proteins 0.000 claims 2
- VYLJAYXZTOTZRR-BTPDVQIOSA-N CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C Chemical compound CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C VYLJAYXZTOTZRR-BTPDVQIOSA-N 0.000 claims 2
- 102000012192 Cystatin C Human genes 0.000 claims 2
- 108010061642 Cystatin C Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 2
- 102100023195 Nephrin Human genes 0.000 claims 2
- 102100036037 Podocin Human genes 0.000 claims 2
- 101710162479 Podocin Proteins 0.000 claims 2
- 102000048176 Prostaglandin-D synthases Human genes 0.000 claims 2
- 108030003866 Prostaglandin-D synthases Proteins 0.000 claims 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
- 229950006323 angiotensin ii Drugs 0.000 claims 2
- 239000005549 deoxyribonucleoside Substances 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000024924 glomerular filtration Effects 0.000 claims 2
- VYLJAYXZTOTZRR-UHFFFAOYSA-N hopane-6alpha,7beta,22-triol Natural products C12CCC3C4(C)CCCC(C)(C)C4C(O)C(O)C3(C)C1(C)CCC1C2(C)CCC1C(C)(O)C VYLJAYXZTOTZRR-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 108010027531 nephrin Proteins 0.000 claims 2
- 239000003087 receptor blocking agent Substances 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical group C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- IHLOTZVBEUFDMD-UUOKFMHZSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,2-dioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 IHLOTZVBEUFDMD-UUOKFMHZSA-N 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 102000013382 Gelatinases Human genes 0.000 claims 1
- 108010026132 Gelatinases Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 102000013519 Lipocalin-2 Human genes 0.000 claims 1
- 108010051335 Lipocalin-2 Proteins 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 201000002429 X-linked Alport syndrome Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261711514P | 2012-10-09 | 2012-10-09 | |
| US61/711,514 | 2012-10-09 | ||
| US201361779137P | 2013-03-13 | 2013-03-13 | |
| US61/779,137 | 2013-03-13 | ||
| PCT/US2013/063884 WO2014058881A1 (en) | 2012-10-09 | 2013-10-08 | Methods for treatment of alport syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253345A Division JP2018080190A (ja) | 2012-10-09 | 2017-12-28 | アルポート症候群の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536301A JP2015536301A (ja) | 2015-12-21 |
| JP2015536301A5 true JP2015536301A5 (enExample) | 2016-12-01 |
| JP6272880B2 JP6272880B2 (ja) | 2018-01-31 |
Family
ID=49382663
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535891A Active JP6272880B2 (ja) | 2012-10-09 | 2013-10-08 | アルポート症候群の処置方法 |
| JP2017253345A Pending JP2018080190A (ja) | 2012-10-09 | 2017-12-28 | アルポート症候群の処置方法 |
| JP2019189071A Pending JP2020073479A (ja) | 2012-10-09 | 2019-10-16 | アルポート症候群の処置方法 |
| JP2022083586A Pending JP2022110140A (ja) | 2012-10-09 | 2022-05-23 | アルポート症候群の処置方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253345A Pending JP2018080190A (ja) | 2012-10-09 | 2017-12-28 | アルポート症候群の処置方法 |
| JP2019189071A Pending JP2020073479A (ja) | 2012-10-09 | 2019-10-16 | アルポート症候群の処置方法 |
| JP2022083586A Pending JP2022110140A (ja) | 2012-10-09 | 2022-05-23 | アルポート症候群の処置方法 |
Country Status (34)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2857881A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| DK2702155T3 (en) | 2011-04-25 | 2017-05-01 | Regulus Therapeutics Inc | MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY |
| NZ630591A (en) | 2012-04-25 | 2017-02-24 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| US9994846B2 (en) | 2013-10-25 | 2018-06-12 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-21 activity |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3171889A4 (en) * | 2014-07-25 | 2018-03-14 | Goldfinch Biopharma, Inc. | Collagen iv replacement |
| CA2958585C (en) | 2014-08-21 | 2024-01-09 | Stealth Biotherapeutics Corp | Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| US11083745B2 (en) | 2015-12-14 | 2021-08-10 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome |
| US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| JP7072748B2 (ja) | 2016-12-28 | 2022-05-23 | 国立大学法人神戸大学 | アルポート症候群治療薬 |
| CN116585344A (zh) * | 2017-05-04 | 2023-08-15 | 赛诺菲 | 用于治疗奥尔波特综合征的方法 |
| WO2018226900A2 (en) | 2017-06-06 | 2018-12-13 | Zymergen Inc. | A htp genomic engineering platform for improving fungal strains |
| EP3878961A1 (en) | 2017-06-06 | 2021-09-15 | Zymergen, Inc. | A htp genomic engineering platform for improving escherichia coli |
| SMT202400071T1 (it) | 2017-08-25 | 2024-03-13 | Stoke Therapeutics Inc | Oligomeri antisenso per il trattamento di condizioni e malattie |
| HRP20250322T1 (hr) | 2017-10-23 | 2025-06-06 | Stoke Therapeutics, Inc. | Protusmisleni oligomeri, namijenjeni liječenju stanja i bolesti uzrokovanih raspadanjem rna posredovanim besmislenim mutacijama |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| WO2020092704A1 (en) | 2018-10-31 | 2020-05-07 | Zymergen Inc. | Multiplexed deterministic assembly of dna libraries |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| JP2022524043A (ja) | 2019-03-08 | 2022-04-27 | ザイマージェン インコーポレイテッド | 微生物の反復ゲノム編集 |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3173647A1 (en) | 2020-05-11 | 2021-11-18 | Isabel AZNAREZ | Opa1 antisense oligomers for treatment of conditions and diseases |
| WO2023217764A1 (en) * | 2022-05-09 | 2023-11-16 | Calliditas Therapeutics Suisse Sa | Nox inhibitors for use in the treatment of alport syndrome |
| WO2024238950A1 (en) * | 2023-05-18 | 2024-11-21 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| WO2025110217A1 (ja) * | 2023-11-22 | 2025-05-30 | 国立大学法人東海国立大学機構 | 嚢胞性腎疾患の予防及び／又は治療剤 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1038886B (zh) * | 1998-05-22 | 2005-09-23 | 博伊斯镇国家研究医院 | α1β1整合蛋白受体抑制剂和TGF-β1抑制剂制备用於治疗肾病的药物组合物的用途 |
| CZ296262B6 (cs) | 1998-05-22 | 2006-02-15 | Boys Town National Research Hospital | Farmaceutický prostredek |
| US20060008817A1 (en) | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
| IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
| US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| ITMI20032528A1 (it) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US7585550B2 (en) | 2004-02-02 | 2009-09-08 | College Of William And Mary | Process for modifying polymeric surfaces using deep UV irradiation |
| AU2005250432B2 (en) | 2004-05-28 | 2011-09-15 | Asuragen, Inc. | Methods and compositions involving microRNA |
| WO2006020768A2 (en) | 2004-08-10 | 2006-02-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| JP2008512463A (ja) * | 2004-09-08 | 2008-04-24 | ボーイズ タウン ナショナル リサーチ ホスピタル | マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療 |
| CA2857881A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| EP1959012A3 (en) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
| US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
| DK1931780T3 (en) * | 2005-08-29 | 2016-01-25 | Regulus Therapeutics Inc | Antisense-forbindelser med forøget anti-microrna-aktivitet |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| ES2569558T3 (es) | 2006-04-03 | 2016-05-11 | Roche Innovation Center Copenhagen A/S | Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi |
| MX2008012219A (es) | 2006-04-03 | 2008-10-02 | Santaris Pharma As | Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn. |
| WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| US8906870B2 (en) | 2006-10-09 | 2014-12-09 | Julius-Maximilians-Universitaet Wuerzberg | MicroRNA (miRNA) for the diagnosis and treatment of heart diseases |
| WO2008073920A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| EP2118118B1 (en) | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
| WO2008151631A2 (en) | 2007-06-15 | 2008-12-18 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| CA2691691C (en) * | 2007-06-20 | 2013-09-24 | Seth J. Baum | Compositions and methods of treating chronic kidney disease |
| AU2008306327B2 (en) | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
| JP5535076B2 (ja) | 2007-10-29 | 2014-07-02 | レグルス・セラピューティクス・インコーポレイテッド | 肝臓癌を治療するための標的化ミクロｒｎａ |
| WO2009091972A2 (en) | 2008-01-18 | 2009-07-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
| JP2011510678A (ja) * | 2008-02-08 | 2011-04-07 | プロセンサ ホールディング ビーブイ | Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段 |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
| CA2753562A1 (en) | 2009-02-26 | 2010-09-02 | The Ohio State University Research Foundation | Micrornas in never-smokers and related materials and methods |
| US20120148664A1 (en) | 2009-06-08 | 2012-06-14 | Miragen Therapeutics | Chemical modifications motifs for mirna inhibitors and mimetics |
| WO2011126842A2 (en) | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| DK2702155T3 (en) | 2011-04-25 | 2017-05-01 | Regulus Therapeutics Inc | MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY |
| WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| NZ630591A (en) | 2012-04-25 | 2017-02-24 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
| CN104685056A (zh) | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| CA2886116C (en) | 2012-09-26 | 2022-06-07 | Mirrx Therapeutics | Oligomers with improved off-target profile |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2013
- 2013-08-10 UA UAA201504453A patent/UA116639C2/uk unknown
- 2013-10-08 KR KR1020237031594A patent/KR20230136686A/ko not_active Withdrawn
- 2013-10-08 DK DK13777458T patent/DK2906698T3/da active
- 2013-10-08 KR KR1020157009045A patent/KR102165189B1/ko active Active
- 2013-10-08 CN CN201380051249.9A patent/CN104718295B/zh active Active
- 2013-10-08 MX MX2015004460A patent/MX356340B/es active IP Right Grant
- 2013-10-08 ES ES19188663T patent/ES2960488T3/es active Active
- 2013-10-08 CA CA2885605A patent/CA2885605A1/en active Pending
- 2013-10-08 KR KR1020227000173A patent/KR20220005634A/ko not_active Ceased
- 2013-10-08 PT PT137774584T patent/PT2906698T/pt unknown
- 2013-10-08 AR ARP130103643A patent/AR092940A1/es not_active Application Discontinuation
- 2013-10-08 KR KR1020207028577A patent/KR102349184B1/ko active Active
- 2013-10-08 ES ES13777458T patent/ES2753174T3/es active Active
- 2013-10-08 HR HRP20191948TT patent/HRP20191948T1/hr unknown
- 2013-10-08 US US14/048,827 patent/US9012423B2/en active Active
- 2013-10-08 EP EP13777458.4A patent/EP2906698B1/en active Active
- 2013-10-08 RS RS20191380A patent/RS60014B1/sr unknown
- 2013-10-08 LT LT13777458T patent/LT2906698T/lt unknown
- 2013-10-08 UY UY35069A patent/UY35069A/es not_active Application Discontinuation
- 2013-10-08 NZ NZ630596A patent/NZ630596A/en not_active IP Right Cessation
- 2013-10-08 PL PL13777458T patent/PL2906698T3/pl unknown
- 2013-10-08 AU AU2013329427A patent/AU2013329427B2/en not_active Ceased
- 2013-10-08 BR BR112015007709-9A patent/BR112015007709B1/pt not_active IP Right Cessation
- 2013-10-08 SI SI201331597T patent/SI2906698T1/sl unknown
- 2013-10-08 WO PCT/US2013/063884 patent/WO2014058881A1/en not_active Ceased
- 2013-10-08 EP EP19188663.9A patent/EP3620522B1/en active Active
- 2013-10-08 HU HUE13777458A patent/HUE045858T2/hu unknown
- 2013-10-08 JP JP2015535891A patent/JP6272880B2/ja active Active
- 2013-10-08 TW TW102136388A patent/TWI641388B/zh active
- 2013-10-08 MY MYPI2015000876A patent/MY183921A/en unknown
- 2013-10-08 SG SG11201502748RA patent/SG11201502748RA/en unknown
- 2013-10-08 EA EA201590711A patent/EA201590711A1/ru unknown
-
2015
- 2015-03-16 IL IL237768A patent/IL237768B/en active IP Right Grant
- 2015-03-16 TN TNP2015000099A patent/TN2015000099A1/fr unknown
- 2015-03-26 ZA ZA2015/02087A patent/ZA201502087B/en unknown
- 2015-04-02 US US14/677,387 patent/US9359609B2/en active Active
- 2015-04-07 CL CL2015000873A patent/CL2015000873A1/es unknown
- 2015-04-08 PH PH12015500781A patent/PH12015500781B1/en unknown
- 2015-05-07 CR CR20150236A patent/CR20150236A/es unknown
-
2016
- 2016-05-10 US US15/151,290 patent/US9688986B2/en active Active
-
2017
- 2017-05-26 US US15/606,554 patent/US9970011B2/en active Active
- 2017-12-28 JP JP2017253345A patent/JP2018080190A/ja active Pending
-
2018
- 2018-04-09 US US15/948,450 patent/US20180298385A1/en not_active Abandoned
- 2018-10-08 IL IL262200A patent/IL262200A/en unknown
-
2019
- 2019-07-29 AU AU2019210494A patent/AU2019210494A1/en not_active Abandoned
- 2019-10-16 JP JP2019189071A patent/JP2020073479A/ja active Pending
- 2019-10-30 CY CY20191101129T patent/CY1122479T1/el unknown
-
2020
- 2020-01-21 US US16/747,837 patent/US20200283765A1/en not_active Abandoned
-
2021
- 2021-07-02 US US17/366,796 patent/US20220098582A1/en not_active Abandoned
- 2021-11-18 AU AU2021269404A patent/AU2021269404A1/en not_active Abandoned
-
2022
- 2022-05-23 JP JP2022083586A patent/JP2022110140A/ja active Pending
-
2023
- 2023-07-21 US US18/356,404 patent/US20240167032A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536301A5 (enExample) | ||
| JP2022110140A (ja) | アルポート症候群の処置方法 | |
| HRP20210616T1 (hr) | Spojevi mikrornk i postupci za moduliranje aktivnosti mir-21 | |
| JP2014518619A5 (enExample) | ||
| JP2018528945A5 (enExample) | ||
| JP2018530325A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| RU2018108206A (ru) | Способы лечения поликистозной болезни почек | |
| ES2988845T3 (es) | Procedimientos predictivos y diagnósticos para cáncer de próstata | |
| JP2019536803A5 (enExample) | ||
| US20240115598A1 (en) | Methods for Treatment of Alport Syndrome | |
| Roberts et al. | Adenosine receptor expression in the development of renal fibrosis following ischemic injury | |
| KR20190093207A (ko) | 다낭성 신장 질환의 치료 방법 | |
| CN102716123B (zh) | 一种用于治疗IgA肾病复方制剂 | |
| JP2020518633A5 (enExample) | ||
| WO2023122656A1 (en) | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors | |
| Tan et al. | Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats | |
| JP2008540448A (ja) | 糖尿病性腎症の治療において、スロデキシド及び血圧低下薬を用いた併用療法 | |
| EP4615974A1 (en) | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |